High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...
"Its history includes some of the major scientific advances of the nineteenth and twentieth centuries…" On 18th May 1999, Sanofi and Synthélabo officially came together in Paris, France to form ...
Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: • €850 million floating rate notes, due March 2027, bearing interest at 3-month Euribor ...
Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the country. The latest ...
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
3d
MedPage Today on MSNHigh-Dose Vitamin D Reduces Disease Activity in Early Multiple Sclerosis"It was important to conduct a large randomized controlled trial to evaluate the efficacy of high-dose cholecalciferol as ...
11h
Investing News Network on MSNBird Flu Vaccine Stocks: 8 Companies Developing H5N1 VaccinesLife science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...
The statement by the Minister of Industry, Trade and Investment, Jumoke Oduwole that 30 foreign trips undertaken by President Bola Tinubu have attracted proposed investments worth $50.8 billion into ...
Ipsen's 2024 dividend per share amounted to EUR 1.20. We view Ipsen's shareholder distributions as mixed as many other biotechnology companies under our coverage do not pay dividends. We anticipate ...
The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...
Pharma - STADA, a leading healthcare and pharmaceutical company in Consumer Healthcare, Generics and Specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results